[Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
Katedra i Klinika Hematologii i Transplantacji Szpiku Si. AM w Katowicach.
Grzegorz
G
Helbig
Beata
B
Stella-Hołowiecka
Jerzy
J
Hołowiecki
D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy*; D000068877:Imatinib Mesylate; D015514:Oncogene Proteins, Fusion / Q000187:drug effects / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000187:drug effects / Q000378:metabolism*; D039221:mRNA Cleavage and Polyadenylation Factors / Q000187:drug effects / Q000378:metabolism*
D000970:Antineoplastic Agents; D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha